BioMarin Pharmaceutical stock fell 2.16 percent after Pompe data

Published on 10/04/2026 at 09:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioMarin Pharmaceutical stock was last at USD 57.18 on Nasdaq on October 2, 2026. Second-quarter revenue reached USD 989.71 million, up 20 percent year over year.

BMRN, US09061G1013, Illustration mit AI erstellt.

BioMarin Pharmaceutical stock (ISIN US09061G1013) was last at USD 57.18 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 2.16 percent from the prior close. The move followed five-year clinical data for POMBILITI and OPFOLDA in late-onset Pompe disease, released by BioMarin on October 2, 2026.

Pompe study reaches five years

The Phase 3 PROPEL open-label extension included 82 people who continued combination treatment from the original study baseline through year five, according to BioMarin. In the previously treated group, predicted six-minute walk distance increased 0.7 percent from baseline, while predicted forced vital capacity declined 2.8 percent through year five.

The safety profile adds a counterweight to the efficacy readings: treatment-related adverse events affected 51.2 percent of participants, or 42 people, and five participants discontinued treatment for safety reasons. That combination of durable walking performance and measurable pulmonary decline gives the data a mixed clinical profile rather than a simple positive read-through.

Quarterly numbers beat expectations

BioMarin's second-quarter revenue was USD 989.71 million, up 20 percent from the same quarter a year earlier, while EPS reached USD 1.20 versus the USD 0.95 consensus, MarketBeat reported on October 1, 2026. The USD 0.25 EPS beat and the 20 percent revenue growth provide a stronger operating comparison than the clinical headline alone.

The same report said BioMarin set fiscal 2026 EPS guidance at USD 4.900-5.100. That guidance frames the valuation discussion because the latest Nasdaq price stood below the average 12-month analyst target of USD 89.17 from 24 brokerages.

Stock remains below yearly high

BioMarin's October 2 Nasdaq range was USD 49.26 to USD 70.98 over 52 weeks, with a market capitalization of USD 11.1 billion and volume of 2,194,469 shares. The USD 57.18 price sat USD 13.80 below the yearly high, leaving clinical durability, revenue growth and earnings execution as the main measurable markers for the stock.